The article discusses the resolution of acute inflammation, emphasizing that it is an active process involving endogenous biochemical pathways that counteract inflammation and promote tissue repair. It highlights the importance of defining terms and mechanisms involved in resolution, such as the role of leukocytes, lipid mediators, chemokines, and cytokines. The resolution phase involves the clearance of inflammatory cells, the return of tissue to homeostasis, and the reversion of parenchymal cells to a non-inflammatory state. The article also discusses the role of toll-like receptors (TLRs) and NOD-like receptors (NLRs) in recognizing pathogens and initiating resolution. It emphasizes the need for new therapeutic approaches that target resolution rather than merely inhibiting inflammation, as current anti-inflammatory drugs often fail to achieve permanent resolution. The article also highlights the importance of understanding the molecular mechanisms of resolution, including the role of endogenous mediators such as lipoxins and resolvins, and the potential of drugs that promote resolution. It discusses the clinical implications of non-resolving inflammation, the need for new clinical measurements to assess resolution, and the potential of drugs that enhance resolution. The article concludes that understanding the resolution process is crucial for developing new therapies for inflammatory diseases.The article discusses the resolution of acute inflammation, emphasizing that it is an active process involving endogenous biochemical pathways that counteract inflammation and promote tissue repair. It highlights the importance of defining terms and mechanisms involved in resolution, such as the role of leukocytes, lipid mediators, chemokines, and cytokines. The resolution phase involves the clearance of inflammatory cells, the return of tissue to homeostasis, and the reversion of parenchymal cells to a non-inflammatory state. The article also discusses the role of toll-like receptors (TLRs) and NOD-like receptors (NLRs) in recognizing pathogens and initiating resolution. It emphasizes the need for new therapeutic approaches that target resolution rather than merely inhibiting inflammation, as current anti-inflammatory drugs often fail to achieve permanent resolution. The article also highlights the importance of understanding the molecular mechanisms of resolution, including the role of endogenous mediators such as lipoxins and resolvins, and the potential of drugs that promote resolution. It discusses the clinical implications of non-resolving inflammation, the need for new clinical measurements to assess resolution, and the potential of drugs that enhance resolution. The article concludes that understanding the resolution process is crucial for developing new therapies for inflammatory diseases.